AbbVie ABBV has built a substantial neuroscience franchise. While the segment was initially anchored by Botox Therapeutic and the depression drug Vraylar, its offerings now include the oral migraine ...

AbbVie ABBV has built a robust neuroscience franchise over the years. Though the segment was initially heralded by blockbuster medications like Botox Therapeutic and the depression drug Vraylar, the ...

A number of pivotal announcements this year – including Neuralink’s first brain implant trial, and major funding rounds from companies such as Motif Neurotech with its miniaturized neurostimulator for ...

Long-term investors shouldn't overlook this top pharma stock and top medical device maker. AbbVie is seeing impressive growth from both its immunology portfolio and neuroscience products. Medtronic is ...